TREA

79309391 - NAVIGATION DRUG

Follow

Information

  • Trademark
  • 79309391
  • Serial Number
    79309391
  • Registration Number
    6720814
  • Filing Date
    December 21, 2020
    4 years ago
  • Registration Date
    May 24, 2022
    2 years ago
  • Transaction Date
    May 02, 2023
    a year ago
  • Status Date
    May 24, 2022
    2 years ago
  • Published for Opposition Date
    February 22, 2022
    2 years ago
  • Location Date
    March 28, 2023
    a year ago
  • Status Code
    700
  • Current Location
    TMO LAW OFFICE 111
    Employee Name
    FALK, JONATHAN ROBERT
  • Attorney Docket Number
    TOYO0011WOUS
    Attorney Name
    Mary Margaret L. O'Donnell
    Law Office Assigned Location Code
    M20
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
NAVIGATION DRUG
Case File Statements
  • B00001: In the statement, lines 2 thru 4, " EAREE Bldg. 5F, 35-100, Kita-8jo-Nishi 18-chome, Chuo-ku Japan" should be deleted, and EAREE Bldg. 5F, 35-100, Kita-8jo-Nishi 18-chome, Chuo-ku Sapporo-shi, Hokkaido Japan 060-0008 should be inserted.
  • GS0051: Pharmaceutical preparations and substances for the diagnosis and treatment, and the prevention of breast, brain, colorectal and gastro-intestinal cancer; pharmaceutical preparations and substances used for detecting body fluids; pharmaceutical preparations and substances used for detecting pancreatic fluids; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of cancer; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of digestive system disorders; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of bone diseases; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of hyperlipidemia diseases; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of gastrointestinal diseases; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of hypoglycemia; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of sarcoma; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of immune system diseases and disorders; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of hypertension; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of respiratory diseases and disorders; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of skin disorders; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of multiple sclerosis; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of cardiovascular diseases; pharmaceutical preparations for treating peripheral nervous system disorders; pharmaceutical preparations for treating central nervous system disorders; diagnostic biomarker reagents for medical purposes; veterinary diagnostic reagents; fluorescent diagnostic reagents for veterinary purposes; fluorescent diagnostic test reagents for veterinary purposes; diagnostic test reagents for medical purposes; fluorescent diagnostic test reagents for medical purposes; fluorescent diagnostic reagents for medical purposes; pharmaceutical preparations and other preparations for destroying vermin, fungicides, herbicides; fluorescent medical diagnostic reagents; chemical reagents for veterinary purposes; fluorescent chemical reagents for veterinary purposes; chemical reagents for medical purposes; fluorescent chemical reagents for medical purposes; reagents for medical purposes; fluorescent reagents for medical purposes; medical diagnostic reagents and assays for testing of body fluids; medical diagnostic reagents and analysis samples for testing of body fluids; medical fluorescent diagnostic reagents and assays for testing of body fluids; medical fluorescent diagnostic reagents and analysis samples for testing of body fluids; medical clinical diagnostic reagents; fluorescent reagents for the clinical diagnosis; therapeutic drugs and agents, namely, agents for the treatment of malignant tumors
  • GS0011: Reagents for research purposes; reagents for chemical analyses other than for medical or veterinary purposes; reagents for use in scientific apparatus for chemical or biological analysis; diagnostic reagents for scientific or research use; diagnostic reagents and preparations, except for medical or veterinary use; chemicals, namely, chemicals used in industry, sulfonates, chemicals for use in agriculture, except fungicides, herbicides, insecticides and parasiticides
  • GS0441: Medical testing services using fluorescent reagents for diagnostic or treatment purposes; medical analysis services for the analysis, diagnosis, and treatment of patients using fluorescent reagents provided by medical laboratories; medical analysis for the diagnosis and treatment of persons; medical diagnostic services; medical evaluation of breast, brain, colorectal and gastro-intestinal cancer; medical diagnostic services using fluorescent reagents; medical evaluation services of breast, brain, colorectal and gastro-intestinal cancer using fluorescent reagents; diagnosis of diseases; diagnosis of diseases using fluorescent reagents; diagnosis of cancer; diagnosis of cancer using fluorescent reagents; medical testing services relating to the diagnosis and treatment of disease; medical testing services relating to the diagnosis and treatment of disease using fluorescent reagents; medical analysis services relating to the diagnosis and treatment of disease using fluorescent reagents provided by medical laboratories; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical analysis for the diagnosis of cancer; cancer screening services; cancer screening services using fluorescent reagents; medical services for the analysis of samples taken from patients provided by medical laboratories; fluorescence imaging examination for the medical diagnosis or treatment; providing information in the field of cancer prevention, screening, diagnosis and treatment; providing medical information; providing medical information on diagnosis using fluorescent reagents; providing information on medical diagnosis using fluorescent reagents; medical analysis for the diagnosis of cancer using fluorescent reagents; rental of medical apparatus and installations; rental of medical diagnostic apparatus and installations; rental of medical diagnostic apparatus using fluorescent reagents and medical apparatus and installations using fluorescent reagents
  • D10000: "DRUG"
Case File Event Statements
  • 5/2/2023 - a year ago
    39 - NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED Type: NURC
  • 3/28/2023 - a year ago
    38 - CASE ASSIGNED TO POST REGISTRATION PARALEGAL Type: APRE
  • 3/28/2023 - a year ago
    37 - CORRECTION UNDER SECTION 7 ¿ PROCESSED Type: COC.
  • 3/23/2023 - a year ago
    36 - CASE ASSIGNED TO POST REGISTRATION PARALEGAL Type: APRE
  • 10/3/2022 - 2 years ago
    35 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO
  • 9/13/2022 - 2 years ago
    34 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS
  • 9/13/2022 - 2 years ago
    33 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 8/24/2022 - 2 years ago
    32 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 7/7/2022 - 2 years ago
    31 - TEAS SECTION 7 REQUEST RECEIVED Type: ES7R
  • 5/24/2022 - 2 years ago
    30 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC
  • 5/24/2022 - 2 years ago
    29 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 2/22/2022 - 2 years ago
    28 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 2/22/2022 - 2 years ago
    27 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 2/20/2022 - 2 years ago
    26 - NOTIFICATION PROCESSED BY IB Type: GPNX
  • 2/2/2022 - 3 years ago
    25 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 2/2/2022 - 3 years ago
    24 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R
  • 2/2/2022 - 3 years ago
    23 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 1/18/2022 - 3 years ago
    22 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 1/13/2022 - 3 years ago
    21 - PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED Type: AMPX
  • 1/13/2022 - 3 years ago
    20 - TEAS VOLUNTARY AMENDMENT RECEIVED Type: PARI
  • 12/22/2021 - 3 years ago
    19 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 12/22/2021 - 3 years ago
    18 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 12/22/2021 - 3 years ago
    17 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 12/21/2021 - 3 years ago
    16 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN
  • 12/21/2021 - 3 years ago
    15 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 12/21/2021 - 3 years ago
    14 - TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS Type: ECDR
  • 12/21/2021 - 3 years ago
    13 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 12/21/2021 - 3 years ago
    12 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 12/21/2021 - 3 years ago
    11 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR
  • 8/1/2021 - 3 years ago
    10 - REFUSAL PROCESSED BY IB Type: RFNT
  • 7/12/2021 - 3 years ago
    9 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 7/12/2021 - 3 years ago
    8 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 7/3/2021 - 3 years ago
    7 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP
  • 6/25/2021 - 3 years ago
    6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 6/24/2021 - 3 years ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 6/16/2021 - 3 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 4/27/2021 - 3 years ago
    3 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 4/23/2021 - 3 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 4/22/2021 - 3 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR